Is this the best way to cook pasta?
Cooking pasta al dente, meaning firm to the bite, is recommended by nutritionists to help manage blood sugar levels.
Overcooked pasta can release starch, and also cause a rapid spike in blood sugar, increasing risks for heart disease and other complications.
Al dente pasta is more digestible and has a lower glycemic index, leading to a slower absorption of glucose.
A lower glycemic index helps maintain stable blood sugar, which is beneficial for overall health, particularly for individuals with diabetes, and can promote longer-lasting satiety.
Avoid rinsing pasta after cooking, as this washes away beneficial starches and nutrients.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
34 minutes ago
- The Guardian
Patients dying of sepsis because medics too slow to spot it, warns NHS watchdog
Sepsis is causing thousands of deaths a year, a charity has said, as the NHS's safety watchdog warned that doctors and nurses are too often slow to identify and treat it. 'The recognition of sepsis remains an urgent and persistent safety risk', despite previous reports highlighting the large number of deaths it causes when diagnosed too late, according to the Health Services Safety Investigations Body. Too often, relatives were ignored when they raised concerns about the condition of a loved one who later died of sepsis, the HSSIB said on Thursday. It urged NHS trusts and staff in England to learn from mistakes which the UK Sepsis Trust estimates play a key role in as many as 10,000 avoidable deaths every year UK-wide. Sepsis develops when an infection goes untreated and the body's immune response starts to target its own tissues and organs. Doctors refer to that process as 'organ dysfunction'. It causes more deaths than lung cancer and is the second biggest killer in England after heart disease, NHS England says. However, it is very hard to diagnose as many of its symptoms – such as confusion, breathlessness and blotchy skin – are also found with other conditions and there is no single sign or diagnostic test to identify it. The report from HSSIB is the latest in a series from bodies including the Parliamentary and Health Service Ombudsman (PHSO) and Care Quality Commission to reveal the large number of patients who die every year after NHS staff take too long to diagnose it. 'There have been initiatives to improve the recognition and timely treatment of sepsis over the last 20 years, yet it has persisted as a safety risk,' HSSIB said. It published reports of three cases involving patients – named only as Barbara, Ged and Lorna – for whom a delay in spotting sepsis had severe consequences. Two of the patients died and the third had to have her leg amputated below the knee after starting on antibiotics too late. The three incidents 'show a consistent pattern of issues around the early recognition and treatment of sepsis', said Melanie Ottewill, HSSIB's senior safety investigator. 'The experiences of Barbara, Ged and Lorna show the devastating consequences of sepsis. They also highlight the imperative of listening to families when they express concerns about their loved one and tell us about changes in how they are.' Lorna was admitted to hospital in England on 5 July last year with severe abdominal pain and a high heart rate. It took 30 hours before a doctor identified her sepsis and gave her antibiotics. However, her condition deteriorated and she died the next day. 'Lorna's family expressed concerns that they were unable to advocate for her wellbeing and that their concerns about how unwell she was were not always heard,' HSSIB said. Dr Ron Daniels, the founder and chief medical officer of the UK Sepsis Trust, said that since the success of hospitals in England in 2016-19 at identifying and promptly treating sepsis, the NHS's performance 'has slipped backwards considerably'. That is because a financial incentive offered to hospitals, to screen anyone who might have sepsis and give them antibiotics within an hour – the approach recommended by the National Institute for Health and Care Excellence – ended. 'The quality of care has returned to its pre-2016 level – that is, a postcode lottery in patients' chances of their sepsis being spotted. I'm appalled,' Daniels said. 'We estimate that of the 48,000 people a year who die of sepsis, at least 10,000 more lives could be saved if the NHS prioritised sepsis as an urgent clinical issue.' Rebecca Hilsenrath, chief executive of the PHSO, said: 'These reports highlight what we have been saying about sepsis for over a decade. Lessons are not being learned, recommendations from reports are not being implemented and mistakes are putting people at risk.' The NHS's culture needs to be one that is 'open, accepts mistakes and learns from them' in order to reduce the huge toll of avoidable death, she added.
The Guardian
2 hours ago
- The Guardian
Equivalent of one child in every British classroom now born via IVF, data shows
The proportion of women giving birth after fertility treatment in the UK has increased by more than a third in a decade, with the equivalent of one child in every classroom now born as a result of IVF, figures show. One in 32 births in 2023 were the result of in vitro fertilisation, up 34% from one in 43 in 2013, according to the Human Fertilisation and Embryology Authority (HFEA). Overall in 2023, 52,400 patients had more than 77,500 IVF cycles at licensed fertility clinics in the UK, while about 20,700 babies were born via the process, up from 8,700 in 2000, the fertility regulator said. The number of women freezing their eggs also increased sharply, with cycles up from 4,700 in 2022 to 6,900 in 2023. Egg freezing increased most among women in their 30s, but the number using their stored frozen eggs remained low, the report said. IVF births now make up a higher proportion of all UK births, increasing from 1.3% in 2000 to 3.1% in 2023. 'This means around one in 32 UK births in 2023 were via IVF – roughly one child in every classroom – compared to one in 43 in 2013,' the report said. For women aged 40-44, 11% of births were as a result of IVF, up from 4% in 2000, accounting for 0.5% of all births, HFEA said. About 820 babies were born as a result of donor insemination (DI) treatment in 2023. The report also reveals a reduction in the number of IVF treatments funded by the health service. The proportion of NHS-funded IVF cycles declined from 35% in 2019 to 27% in 2023 in the UK, decreasing most in England, the HFEA said. More than half (54%) of IVF cycles in Scotland were funded by the NHS in 2023, compared with 49% in Northern Ireland, 33% in Wales and 24% in England. The HFEA also raised concerns about racial disparities in IVF treatment. In recent years, Asian and black patients have had lower birthrates compared with white patients and those from mixed ethnic backgrounds, according to the report. Julia Chain, the chair of the HFEA, said: 'IVF is helping more people have babies including patients of different ages and family types. One in 32 of all UK births are from IVF … We are also seeing more single patients and female same-sex couples having IVF. These findings highlight the changing landscape of the UK fertility sector and how it could develop in the years to come. 'However, we are very concerned to see that black and Asian patients continue to have lower IVF birthrates compared to other patient groups, and our recent national patient survey found that Asian and black patients are less likely to report being satisfied with their fertility treatment.' The survey also found that of the 80% of fertility patients who spoke to a GP before starting treatment, most waited up to a year to start treatment but 16% waited more than two years. Recent data showed that gynaecology waiting lists were long, Chain said. Anyone with concerns about their fertility should speak to their GP, she added. 'We also encourage all primary care providers to ensure speedy referrals to specialist fertility services, if needed, to ensure the chances of success are as high as possible.' The fertility rate in England and Wales in 2023 was 1.44 children per woman, according to the Office for National Statistics – the lowest level on record.
Sky News
3 hours ago
- Sky News
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator. New figures from the Medicines and Healthcare products Regulatory Agency (MHRA) show the group of drugs that includes Mounjaro, Wegovy, and Ozempic may be associated with inflammation of the pancreas. According to the MHRA, there have been 181 reported cases of acute or chronic pancreatitis linked to Mounjaro, with five deaths. Wegovy and Ozempic have been linked with 113 reports of pancreatitis and one death. Other, less widely used versions of so-called GLP-1 drugs have also been linked to cases and deaths. There is no evidence that the drugs directly caused the deaths. And the evidence isn't strong enough for the MHRA to restrict access. 1:31 That's because pancreatitis also occurs in people who aren't taking the GLP-1 drugs, with about 560 cases for every one million people in the general population. Gallstones and alcohol are the biggest causes. But the MHRA and Genomics England are launching a new study to see whether some people have genes that put them at higher risk of developing pancreatitis if they take GLP-1 drugs. People reported through the MHRA's 'yellow card' alert system to have pancreatitis while using the jabs will be asked to provide a saliva sample and their genes tested. Professor Matt Brown, chief scientific officer of Genomics England, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines, there can be a risk of serious side effects. "We believe there is real potential to minimise these, with many adverse reactions having a genetic cause. "This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription." The main symptoms of pancreatitis are severe pain in the centre of the tummy area, fever and nausea. Acute cases are treated in hospital with fluids and oxygen, and generally make a recovery within a few days. But there can be complications, and around 5% of acute cases are fatal. With all medicines, there is a balance of risk and benefit. For people with type 2 diabetes or obesity, there are clear benefits to using the jabs. They lower blood sugar levels, lead to rapid weight loss and reduce deaths from cardiovascular disease by a fifth. But for people who are a bit overweight and have sourced the jabs privately to lose a few pounds ahead of their summer holiday, the health benefits are far less clear. This is a wake-up call for them. These are powerful medications with effects not just on appetite, but on lots of body organs, including the brain. And pancreatitis is just one of many possible side effects. Lilly, the UK manufacturer of Mounjaro, has said patient safety is its "top priority". The drug's patient information leaflet "warns that inflamed pancreas (acute pancreatitis) is an uncommon side effect (which may affect up to 1 in 100 people)," the statement continued. Lily "also advises patients to talk to their doctor or other healthcare professional before using Mounjaro if they have ever had pancreatitis," it added.
